tetano
Editor, Senior Moderator
J Appl Microbiol. 2017 Nov 7. doi: 10.1111/jam.13628. [Epub ahead of print]
[h=1]A modified dose-response model that describes the relationship between hemagglutination inhibition titer and protection against influenza infection.[/h] Huang Y[SUP]1[/SUP], Anderson SA[SUP]1[/SUP], Forshee RA[SUP]1[/SUP], Yang H[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] Develop a model for quantifying the risk of an adverse human response to influenza virus infection as a function of exposure dose and pre-exposure antibody titer level.
[h=4]METHODS AND RESULTS:[/h] We evaluated the relationship between hemagglutination inhibition (HI) titer (as a measure of specific antibody response) and protection against influenza infection and modeled this relationship by incorporating HI titer as a variable into dose-response models. Using a Maximum Likelihood Estimation approach, the resulting model was capable of providing statistically acceptable fits to most available data.
[h=4]CONCLUSIONS:[/h] The incorporated HI titer dependency in the model quantifies the protective effect of antibody titer. The modeling can be used to predict the protection effectiveness associated with elevated HI titer levels post vaccination to different levels of exposures.
[h=4]SIGNIFICANCE AND IMPACT OF THE STUDY:[/h] The study incorporates HI titer level as a variable into a dose-response model for influenza infection. The approaches developed in this study could be used to evaluate other factors associated with the predictability of HI titer or other surrogate endpoints for influenza vaccines. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Viruses; dose-response modelling; hemagglutination inhibition; influenza infection; protection
PMID: 29112316 DOI: 10.1111/jam.13628
[h=1]A modified dose-response model that describes the relationship between hemagglutination inhibition titer and protection against influenza infection.[/h] Huang Y[SUP]1[/SUP], Anderson SA[SUP]1[/SUP], Forshee RA[SUP]1[/SUP], Yang H[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]AIMS:[/h] Develop a model for quantifying the risk of an adverse human response to influenza virus infection as a function of exposure dose and pre-exposure antibody titer level.
[h=4]METHODS AND RESULTS:[/h] We evaluated the relationship between hemagglutination inhibition (HI) titer (as a measure of specific antibody response) and protection against influenza infection and modeled this relationship by incorporating HI titer as a variable into dose-response models. Using a Maximum Likelihood Estimation approach, the resulting model was capable of providing statistically acceptable fits to most available data.
[h=4]CONCLUSIONS:[/h] The incorporated HI titer dependency in the model quantifies the protective effect of antibody titer. The modeling can be used to predict the protection effectiveness associated with elevated HI titer levels post vaccination to different levels of exposures.
[h=4]SIGNIFICANCE AND IMPACT OF THE STUDY:[/h] The study incorporates HI titer level as a variable into a dose-response model for influenza infection. The approaches developed in this study could be used to evaluate other factors associated with the predictability of HI titer or other surrogate endpoints for influenza vaccines. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] Viruses; dose-response modelling; hemagglutination inhibition; influenza infection; protection
PMID: 29112316 DOI: 10.1111/jam.13628